Clinical Trial Update: Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab [Phase 2]

View source ↗

Summary

This completed Phase II randomized study in inoperable non-squamous non-small cell lung cancer compared Bevacizumab plus Erlotinib versus Gemcitabine/Cisplatin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Gemzar (gemcitabine)
• Platinol (cisplatin)
• Tarceva (erlotinib)

Snippet

Sponsor: Aktion Bronchialkarzinom e.V. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED